Global Large Volume Parenteral Market (2020 to 2025) - Featuring Supramol Laboratory, Albert David & Otsuka Holdings Among Others -

DUBLIN--()--The "Global Large Volume Parenteral (LVP) Market - Forecasts from 2020 to 2025" report has been added to's offering.

The global market for large volume parenteral (LVP) is predicted to grow at a CAGR of 7.08% from a market size of USD7.918 billion in 2019 to achieve a market size of USD11.939 billion by the end of 2025.

Parenterals are referred to as the dosage forms other than the oral route of drug administration, hence the drug administration is performed by the other routes especially, intramuscular, subcutaneous, and intravenous. Large volume parenteral is delivered through an intravenous route of administration and is present in a volume greater than 100ml. These comprise of 100 ml, 250 ml, 500 ml, 1000 ml, and 2000 ml. hence, these are packaged in large amounts for use in many applications for example for nutrition requirements, for the correction of electrolyte & fluid balance disturbances, and as a vehicle for administering other drugs. The growing prevalence of chronic diseases is propelling the market demand in the forecast period.

The prevalence of the number of hospitalizations in a year for the treatment of diseases requiring LVPs is burgeoning the market demand in the forecast period. In the cases of surgeries, LVPs find immense use, hence, the growing number of surgical procedures is also providing an impetus in propelling the market growth in the forecast period. Common large volume parenterals include sodium chloride solution, dextrose solution, Ringer's solution, and lactated Ringer's solution, also the combination of dextrose and sodium chloride. The LVPs serve as a mode of faster drug delivery for patients when in need, particularly at the time of surgeries, hence are quite effective. The growing drug delivery industry is also providing strong growth prospects for the market to proliferate in the forecast period. The increasing demand of patients for single-dose vaccine administration is also fueling the market growth in the forecast period.

However, there are a limited number of producers for the supply of large volume parenterals in the United States, these shortages are due to the manufacturing problems interrupting the production operations in the country. It has been noticed that in spite of high interest for large volume parenterals in the country, very few manufacturers produce these products, hence, an increased demand along with the delay in the manufacturing of LVP, this has further resulted in shortages of important LVPs in the United States of America. Some manufacturers have discontinued the products in certain packaging formats or have withdrawn from the market altogether. According to the second report by the US, Council of Science and Public Health on national drug shortages, the report stated that the problems specifically for the sterile injectables which include the LVPs including product discontinuations accounted for over 80% of the drug shortages in 2014 and 2015. It was reported that there were shortages of sodium chloride (saline) and dextrose solutions that are sold in large volumes for injection.

The company, Grifols has implemented its vertical integration strategy for a constant supply of high-quality sodium chloride 0.9% solution to the blood/plasma centers. The company stated that it will supply these large volume parenterals in 500 ml in 2018. The company, a Spanish pharmaceutical and chemical manufacturer is providing important LVPs to various hospitals, pharmacies, and compounding centers in the US region. The production of high-quality, sterile parenteral drug products consists of complicated processes, hence, there are limited manufacturers producing parenteral goods. Grifols has a long history of producing large volume parenterals for the European region, hence, the company has shown its capability for implementing cost-effective processes for the sustainable production of high-quality parenterals in large volumes.

COVID-19 impact overview of the global large volume parenteral market. It has been widely observed that the ongoing global pandemic crisis is affecting the manufacturing operations of various markets worldwide. This is mainly due to the prevention measures taken by the individuals for the prevention of transmission of the deadly viral disease. Necessary medicines as required for the treatment of the critically-ill patients include cardiac drugs, analgesics, anti-clotting medicines, and medical nutrition along with large volume parenterals, these are at risk of being scarce amid the novel coronavirus scenario. This is due to the soaring demand for these essential medications. Hence, the COVID-19 pandemic is projected to affect the growth of the global large volume parenteral (LVP) market in a negative manner in 2020.

Key Topics Covered:

1. Introduction

2. Research Methodology

3. Executive Summary

4. Market Dynamics

4.1. Market Drivers

4.2. Market Restraints

4.3. Market Opportunities

4.4. Porters Five Forces Analysis

4.5. Industry Value Chain Analysis

5. Large Volume Parenteral Market Analysis, by Volume

5.1. Introduction

5.2. 100 ml - 250 ml

5.3. 250 ml - 500 ml

5.4. Above 500 ml

6. Large Volume Parenteral Market Analysis, by Application

6.1. Introduction

6.2. Correction of electrolyte & fluid balance disturbances

6.3. Nutrition

6.4. Vehicle for administering other drugs

7. Large Volume Parenteral Market Analysis, by Packaging Container

7.1. Introduction

7.2. Glass Bottle

7.3. Plastic Bags

8. Large Volume Parenteral Market Analysis, by Geography

8.1. Introduction

8.2. North America

8.3. South America

8.4. Europe

8.5. Middle East and Africa

8.6. Asia Pacific

9. Competitive Environment and Analysis

9.1. Major Players and Strategy Analysis

9.2. Emerging Players and Market Lucrativeness

9.3. Mergers, Acquisitions, Agreements, and Collaborations

9.4. Vendor Competitiveness Matrix

10. Company Profiles

10.1. Supramol Laboratory

10.2. Albert David Ltd.

10.3. Otsuka Holdings Co., Ltd.

10.4. Grifols S.A.

10.5. B. Braun Melsungen AG

10.6. BML Parenteral Drugs

10.7. Akums Drugs & Pharmaceuticals Ltd.

10.8. D. J. Laboratories Pvt. Ltd.

10.9. Parenteral Drugs (India) Limited

10.10. BKRS Pharma Pvt. Ltd.

For more information about this report visit

Laura Wood, Senior Press Manager

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Laura Wood, Senior Press Manager

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900